DiaMedica Therapeutics Inc.

As of June 30, 2026, DiaMedica Therapeutics Inc. carries a market capitalization of 379.64M, placing it among publicly traded companies globally. Its enterprise value stands at 336.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

DiaMedica Therapeutics Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, DiaMedica Therapeutics Inc. has 53.93M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, DiaMedica Therapeutics Inc. maintains a current ratio of 6.72, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, DiaMedica Therapeutics Inc. posted a negative return on equity (ROE) of -114.62, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -98.18, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 33.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, DiaMedica Therapeutics Inc. recorded 30,000.00 in income tax expense. The company reported a pretax loss of -37.51M and -37.54M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, DiaMedica Therapeutics Inc.'s stock has gained approximately 28.61% over the past 52 weeks. The 50-day moving average sits at 7.31, while the 200-day moving average is 7.09.

Over the twelve months ended June 30, 2026, DiaMedica Therapeutics Inc. generated - - in revenue and converted that into -37.54M in net income, yielding earnings per share of -0.71. EBITDA reached -39.17M, while operating income came in at -39.23M.

As of June 30, 2026, DiaMedica Therapeutics Inc. holds 43.50M in cash and equivalents against 185,000.00 in total debt, resulting in a net debt position of -5.13M. Total book value stands at 38.34M, with working capital of 37.72M providing operational flexibility.

DiaMedica Therapeutics Inc. produced -31.51M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -33,000.00 in capital expenditures, free cash flow totaled -31.54M - equivalent to -0.60 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -8.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -11.64, meaning DiaMedica Therapeutics Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

DiaMedica Therapeutics Inc.'s most recent stock split took place on November 15, 2018 with a 20:1 split ratio.

As of June 30, 2026, DiaMedica Therapeutics Inc. has an Altman Z-Score of 26.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.